CERS
$1.80
Cerus Corporation operates as a biomedical products company.
Recent News
Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference
Cerus (NASDAQ:CERS) executives used a presentation and fireside chat at the TD Cowen Healthcare Conference to reiterate the company’s focus on making its INTERCEPT Blood System a global standard of care for transfusion medicine, while outlining commercial priorities across U.S. platelets, internatio
Cerus Corporation Q4 2025 Earnings Call Summary
Moby summary of Cerus Corporation's Q4 2025 earnings call
Cerus Corp (CERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Cerus Corp (CERS) reports a 16% revenue increase for 2025, driven by strong product sales and strategic agreements, despite challenges in margins and operating expenses.
Cerus Q4 Earnings Call Highlights
Cerus (NASDAQ:CERS) executives highlighted record fourth-quarter and full-year 2025 product revenue, accelerating international momentum, and continued progress toward profitability during the company’s fourth-quarter and full-year 2025 earnings call. 2025 performance and INTERCEPT adoption Chief E
Cerus (CERS) Q4 2025 Earnings Call Transcript
With me on the call are Obi Greenman, Cerus Corporation’s president and chief executive officer; Vivek K. Jayaraman, Cerus Corporation’s chief operating officer; and Kevin D. Green, Cerus Corporation’s chief financial officer. Cerus Corporation issued a press release today announcing our financial results for the fourth quarter and full year ended 12/31/2025, the company's recent business highlights, and outlook.